Racial, Ethnic Disparities in Buprenorphine Treatment Duration

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 9, 2022

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2022.3673?guestAccessKey=98ccf8b9-2207-4814-9bce-9b62cb92b500&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110922

  

About The Study: This analysis found that racial and ethnic disparities in buprenorphine treatment duration increased between 2006 and 2020, particularly during more recent years. Buprenorphine is used to treat opioid use disorder and reduce overdose risk. Duration of buprenorphine treatment is a measure of quality of care; longer retention is associated with superior clinical outcomes.

Authors: Mohammad S. Jalali, Ph.D., of Harvard Medical School in Boston, is the corresponding author.

 

(10.1001/jamapsychiatry.2022.3673)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.